{"nctId":"NCT02698475","briefTitle":"An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age","startDateStruct":{"date":"2016-05","type":"ACTUAL"},"conditions":["Psoriasis"],"count":44,"armGroups":[{"label":"Ustekinumab Group","type":"EXPERIMENTAL","interventionNames":["Drug: Ustekinumab 0.75 mg/kg","Drug: Ustekinumab 45 mg","Drug: Ustekinumab 90 mg"]}],"interventions":[{"name":"Ustekinumab 0.75 mg/kg","otherNames":[]},{"name":"Ustekinumab 45 mg","otherNames":[]},{"name":"Ustekinumab 90 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants who have a diagnosis of plaque-type psoriasis with or without psoriatic arthritis (PsA) for at least 6 months prior to first administration of study drug, with widespread lesions defined by Psoriasis Area and Severity Index score (PASI) greater than or equal to (\\>=) 12, Physician's Global Assessment (PGA) \\>=3, and involved body surface area (BSA) \\>=10 percent (%)\n* Participants who are candidates for phototherapy or systemic treatment of psoriasis (either naive or history of previous treatment) or have psoriasis considered by the investigator as poorly controlled with topical therapy after an adequate dose and duration of therapy\n* Participants who are considered eligible according to the protocol defined tuberculosis (TB) screening criteria\n* Participants must have positive protective antibody titers to varicella and measles prior to the first administration of study drug. In the absence of positive protective antibody titers, the participant must have documentation of age-appropriate vaccination for varicella and/or measles (that includes both doses of each vaccine) or verification of past varicella and/or measles infection documented by a health care provider\n* Participants must agree not to receive a live virus or live bacterial vaccination at least 2 weeks (or longer as indicated in the package insert of the relevant vaccine) prior to the first administration of study drug, during the study, or within 15 weeks after the last administration of study drug\n* Participants must agree not to receive a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening, during the study, or within 12 months after the last administration of study drug\n\nExclusion Criteria:\n\n* Participants who currently have nonplaque forms of psoriasis (example, erythrodermic, guttate, or pustular)\n* Have received any systemic immunosuppressants (example methotrexate \\[MTX\\], azathioprine, cyclosporine, 6-thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, and tacrolimus) within 4 weeks of the first administration of study drug\n* Have received any biologic agent (example ENBREL, HUMIRA) within the previous 3 months or 5 times the t1/2 of the agent, whichever is longer\n* Have a history of chronic or recurrent infectious disease\n* Have a history of latent or active granulomatous infection\n* Have any known malignancy or have a history of malignancy\n* Have a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12","description":"The PGA is used to determine the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), marked (4), or severe (5). Higher scores indicate worse disease. Treatment Failure (TF) criteria- discontinued study agent due to lack of efficacy or adverse event of psoriasis or who started protocol-prohibited medication/therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12","description":"PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 that is none to maximum severity. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. Participants with \\>=75% improvement in PASI from baseline were considered PASI 75 responders. TF criteria- discontinued study agent due to lack of efficacy or adverse event of psoriasis or who started protocol-prohibited medication/therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Children Dermatology Life Quality Index (CDLQI) Score at Week 12","description":"CDLQI was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (Not at all) to 3 (Very much). The total score ranges from 0 to 30, with lower scores indicating better quality of life. The higher the score, the greater the impairment in quality of life (QoL). TF criteria- discontinued study agent due to lack of efficacy or adverse event of psoriasis or who started protocol-prohibited medication/therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","spread":"6.43"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 90 Response at Week 12","description":"PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 that is none to maximum severity. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72 (disease severity). A higher score indicates more severe disease. Participants with \\>=90% improvement in PASI from baseline were considered PASI 90 responders. TF criteria- discontinued study agent due to lack of efficacy or adverse event of psoriasis or who started protocol-prohibited medication/therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a PGA Score of Cleared (0), Cleared (0) or Minimal (1), Mild (2) at Weeks 4, 8, 12, 16, 28, 40, and 52","description":"The PGA is used to determine the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), marked (4), or severe (5). Higher scores indicate worse disease. TF criteria- discontinued study agent due to lack of efficacy or adverse event of psoriasis or who started protocol-prohibited medication/therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a PASI 50, PASI 75, PASI 90 and PASI 100 Response at Weeks 4, 8, 12, 16, 28, 40, and 52","description":"The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4 that is none to maximum severity. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72 (disease severity). PASI 50, 75, 90, and 100 responders were defined as \\>=50%, \\>=75%, \\>=90%, and 100% improvement in PASI from Baseline respectively. TF criteria- discontinued study agent due to lack of efficacy or adverse event of psoriasis or who started protocol-prohibited medication/therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in PASI Score at Weeks 4, 8, 12, 16, 28, 40, and 52","description":"The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4 that is none to maximum severity. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72 (disease severity). PASI 100 responders were defined as 100% improvement in PASI from Baseline respectively. TF criteria- discontinued study agent due to lack of efficacy or adverse event of psoriasis or who started protocol-prohibited medication/therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":"27.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":"21.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.7","spread":"13.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.4","spread":"13.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.4","spread":"21.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":"23.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":"24.28"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved PASI 100, PASI 90, PASI 75 or PASI 50 Response in PASI Components (Induration, Erythema, and Scaling) and Region Components (Head, Trunk, Upper Extremities, and Lower Extremities) at Week 12","description":"The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4 that is none to maximum severity. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72 (disease severity). PASI 50, 75, 90, and 100 responders were defined as \\>=50%, \\>=75%, \\>=90%, and 100% improvement in PASI component from Baseline respectively. TF criteria- discontinued study agent due to lack of efficacy or adverse event of psoriasis or who started protocol-prohibited medication/therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Children Dermatology Life Quality Index (CDLQI) Score at Weeks 4, 12, 28, and 52","description":"CDLQI was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (Not at all) to 3 (Very much). The total score ranges from 0 to 30. The higher the score, the greater the impairment in quality of life (QoL). TF criteria- discontinued study agent due to lack of efficacy or adverse event of psoriasis or who started protocol-prohibited medication/therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"4.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","spread":"6.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"5.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"6.10"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a CDLQI Score of 0 or 1 at Week 12 in Participants With a Baseline CDLQI Score Greater Than (>) 1","description":"CDLQI was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (Not at all) to 3 (Very much). The total score ranges from 0 to 30. The higher the score, the greater impairment in quality of life. TF criteria- discontinued study agent due to lack of efficacy or adverse event of psoriasis or who started protocol-prohibited medication/therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a CDLQI Score of 0 or 1 at Weeks 4, 12, 28 and 52 in Participants With a Baseline CDLQI Score > 1","description":"CDLQI was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (Not at all) to 3 (Very much). The total score ranges from 0 to 30. The total score ranges from 0 to 30. The higher the score, the greater impairment in quality of life. TF criteria- discontinued study agent due to lack of efficacy or adverse event of psoriasis or who started protocol-prohibited medication/therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CDLQI Component Scores at Week 12","description":"CDLQI was used to assess the impact of psoriasis on subject health-related quality of life. The CDLQI has 10 items assessing health-related quality of life (HRQOL) in patients with skin disease each measured on a scale from 0 (Not at all) to 3 (Very much). The total score ranges from 0 to 30. The total score ranges from 0 to 30. The higher the score, the greater impairment in quality of life. TF criteria- discontinued study agent due to lack of efficacy or adverse event of psoriasis or who started protocol-prohibited medication/therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"1.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"2.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.14"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With PGA Score of Cleared (0), Cleared (0) or Minimal (1), Cleared (0) or Minimal (1) or Mild (2) at Weeks 80, 104, 128, 152, and 176","description":"The PGA is used to determine the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), marked (4), or severe (5). Higher scores indicated worse disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":44},"commonTop":["Nasopharyngitis","Injection Site Erythema","Upper Respiratory Tract Infection","Pharyngitis","Gastroenteritis"]}}}